Adverum Biotechnologies (ADVM) said Monday that the 52-week results from its LUNA phase 2 trial and four-year data from the OPTIC trial for Ixo-vec showed reductions in treatment burden for wet age-related macular degeneration patients.
In the LUNA trial, patients receiving the Ixo-vec, or 6E10 dose, demonstrated an 88% reduction in anti-VEGF injections, with 54% of patients being injection-free. These results were supported by four-year OPTIC data, which showed an 86% reduction in annualized anti-VEGF injections.
Adverum also said Ixo-vec was well tolerated across both trials, with inflammation effectively managed using local steroids, and no serious adverse events related to the therapy.
Meanwhile, the company said it has selected the 6E10 dose with topical-eyedrops prophylaxis for its ARTEMIS phase 3 trial, which is expected to begin in H1 2025.
The primary endpoint for the trial will assess non-inferiority in best-corrected visual acuity change between Ixo-vec and aflibercept. All patients enrolled in the phase 3 study will receive three monthly loading doses of aflibercept before transitioning to Ixo-vec.
Adverum said it has an updated cash runway of $153.2 million as of Sept. 30, which is expected to fund operations through the H2 2025.
Shares of the company rose more than 13% in recent premarket activity.
Price: 7.76, Change: +0.90, Percent Change: +13.12
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。